Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Sanofi Global CEO Christopher Viehbacher says he is a great fan of India. With a large market unfolding, Viehbacher knows his priorities. He projects that as much as 40% of Sanofi's sales in the next five years will come from emerging markets like India.

You may also be interested in...



Sanofi Sees Strength In Regional Volatility, GSK Lowers Revenue Target After Price Cuts – Emerging Market Earnings Roundup (Part 4)

In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.

Emerging Views On Emerging Markets: JP Morgan Healthcare Conference (Part 2 of 2)

Emerging markets continued to play a large role in company presentations during the industry’s largest investor conference. In this feature, PharmAsia News takes a closer look.

Sanofi’s Message On Emerging Markets? Catch Us If You Can

Three years ago Sanofi didn’t know it was number one in emerging markets. Now the French pharma can’t talk enough about emerging markets – so what happened?

Table

View full table

Related Content

Scrip
Scrip
Pink Sheet
Scrip
Tags:
Latest Headlines

Finance Watch: Lilly, Fosun Reveal Strategic Investments In Start-Ups, Growth-Stage Firms

Pfizer’s Mixed Readout Places Doubt On Oral GLP-1 For Obesity

Fueled By Lilly And Novo Buy-Outs, Forbion Looks To Make Most Of ‘Buyers’ Market’

Altimmune Regains Some Momentum

See All
UsernamePublicRestriction

Register

SC076449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By